The discovery of a binding site for gallic acid in an unexpected location within the S1-S2 linker at the extracellular face of the VSD on Kv1.1 presents therapeutic possibilities for ataxia and other Kv1.1-linked disorders, including epilepsy. Here, KCNA1 is linked to epilepsy.